|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-10-29
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Angiotensin II and insulin resistance (IR) have clinical implications in the pathophysiology of chronic heart failure (CHF). However, it is still unclear whether the combination of an angiotensin-receptor blocker and angiotensin-converting enzyme inhibitor (ACEI) improves IR in CHF patients who do not receive ?-blockers. Thus, the aim of the present study was to evaluate the effects of losartan on glucose metabolism and inflammatory cytokines in CHF patients treated with ACEI but not ?-blockers.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/CCL2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CCL2,
http://linkedlifedata.com/resource/pubmed/chemical/Enalapril,
http://linkedlifedata.com/resource/pubmed/chemical/IL6 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazolidines,
http://linkedlifedata.com/resource/pubmed/chemical/Inflammation Mediators,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Lisinopril,
http://linkedlifedata.com/resource/pubmed/chemical/Losartan,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/imidapril
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1347-4820
|
|
pubmed:author |
pubmed-author:FuruseYoshiyukiY,
pubmed-author:HisatomeIchiroI,
pubmed-author:IshidaKatsunoriK,
pubmed-author:KaetsuYasuhiroY,
pubmed-author:KatoMasahikoM,
pubmed-author:KinugasaYoshiharuY,
pubmed-author:MizutaEinosukeE,
pubmed-author:OginoKazuhideK,
pubmed-author:ShigemasaChiakiC,
pubmed-author:SugiharaShinobuS,
pubmed-author:YanagiharaKiyotakaK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
74
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2346-52
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20827028-Adrenergic beta-Antagonists,
pubmed-meshheading:20827028-Aged,
pubmed-meshheading:20827028-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:20827028-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:20827028-Biological Markers,
pubmed-meshheading:20827028-Blood Glucose,
pubmed-meshheading:20827028-Chemokine CCL2,
pubmed-meshheading:20827028-Chronic Disease,
pubmed-meshheading:20827028-Cross-Over Studies,
pubmed-meshheading:20827028-Drug Therapy, Combination,
pubmed-meshheading:20827028-Enalapril,
pubmed-meshheading:20827028-Female,
pubmed-meshheading:20827028-Heart Failure,
pubmed-meshheading:20827028-Humans,
pubmed-meshheading:20827028-Imidazolidines,
pubmed-meshheading:20827028-Inflammation Mediators,
pubmed-meshheading:20827028-Insulin,
pubmed-meshheading:20827028-Insulin Resistance,
pubmed-meshheading:20827028-Interleukin-6,
pubmed-meshheading:20827028-Japan,
pubmed-meshheading:20827028-Lisinopril,
pubmed-meshheading:20827028-Losartan,
pubmed-meshheading:20827028-Male,
pubmed-meshheading:20827028-Middle Aged,
pubmed-meshheading:20827028-Time Factors,
pubmed-meshheading:20827028-Treatment Outcome,
pubmed-meshheading:20827028-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without ?-blockers.
|
|
pubmed:affiliation |
Center for Clinical Residency Program, Tottori University Hospital, Yonago, Japan.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
